Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 3/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2294792 | 0.88 | FABP4 (0.48) | FABP4FABP5MAPTGAATHRB | |
| Bromide SCHEMBL2296444 | 0.83 | FFAR1 (0.43) | FFAR1FFAR4LMNAPTGDR2MAPK1 | |
| SCHEMBL14784730 | 0.79 | MAPT (0.47) | FABP4FABP5MAPTGAATHRB | |
| SCHEMBL2292221 | 0.79 | MAPT (0.50) | FABP4FABP5MAPTGAATHRB | |
| Bromide SCHEMBL2293962 | 0.76 | PTPRC (0.41) | MAPTSMN1; SMN2RAB9AFFAR1FFAR4 | |
| SCHEMBL4547676 | 0.76 | MAPT (0.42) | FABP4FABP5MAPTGAATHRB | |
| Hydrochloric Acid SCHEMBL8680808 | 0.75 | SLC6A4 (0.38) | SMN1; SMN2SLC6A4 | |
| Bromide SCHEMBL16268188 | 0.75 | TDP1 (0.41) | MAPTSMN1; SMN2HPGDRAB9ATP53 | |
| Bromide SCHEMBL2675460 | 0.75 | PPARD (0.44) | SLC6A4 | |
| Bromide SCHEMBL5829267 | 0.74 | IDO1 (0.45) | RAB9ANPC1LMNAALDH1A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173704-B2 | Difluorophenol derivatives and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-08 | — | — | US | disclosed |
| US-7998988-B2 | Biphenyl compounds useful in the treatment or prevention of cardiovascular disorders | BAYER SCHERING PHARMA AKTIENGELLSCHAFT (DE) | 2011-08-16 | — | — | US | disclosed |
| US-20090291993-A1 | Difluorophenol Derivatives and Their Use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-26 | — | — | US | disclosed |
| US-20090227640-A1 | Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2009-09-10 | — | — | US | disclosed |
| EP-1940808-A1 | DIFLUOROPHENOL DERIVATIVES AND THEIR USE | Bayer HealthCare AG (DE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007045369-A1 | DIFLUOROPHENOL DERIVATIVES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227640-A1 | Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases | TNNI3, PC, TNNT2 | FABP4 849/4885FABP5 2275/4885MAPT 4498/4885 |
| US-20090291993-A1 | Difluorophenol Derivatives and Their Use | TPMT, FABP3, DPP4 | FABP4 282/4885FABP5 173/4885MAPT 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.